This will be the final editorial from the present team. After almost a decade, PDA is taking the editorial responsibilities over with an internal team. We offer our thoughts and shared experiences below.
Kurt Brorson: It has been a great privilege to serve in the capacity of associate editor of the PDA Journal. It was an opportunity to learn not only the latest in biotech, but also about areas like formulation, small-molecule active pharmaceutical ingredients, and delivery devices outside of my main scientific area of focus. It is a key journal in the interface between industry and academia, and it also tackles regulatory issues. Very few other journals attempt this, and I'm glad to have been part of the effort for the past eight years. Best wishes for the next editorial team!
Beth Junker: As the most recent addition to the editorial team, I was only able to contribute to the journal as an associate editor for a few years. It was an overwhelmingly positive experience to work closely with the rest of the editorial team to facilitate publication of thought-provoking research in the area of regulatory science. Whether submittals were from industrial, academic, or government entities—or a combination thereof—the research topics were always timely and impactful. My best wishes for the new editors and staff in maintaining and improving this useful communication channel for the latest advances in regulatory science.
Tony Moreira: It has been a privilege and an honor to serve for nearly ten years as an associate editor for the PDA Journal of Science and Technology. The Journal occupies a unique position in connecting the bio/pharma industry with academia while interfacing as well with the regulatory side of the house. It was a great personal learning opportunity in which I was amazed with the diversity of topics that our industry covers and the scientific depth of the field. Equally impressive to me was the global source of the articles submitted for publication. I also wish to thank my colleagues on the editorial team for the knowledge they shared and the guidance they were always happy to provide. All the best wishes to the new team, and I will look forward to continuing to benefit from the valuable resource the Journal will provide.
Anurag S. Rathore: After nearly 8 years of serving as an associate editor of the PDA J Sci Technol, it is time to bid adieu. Over the years, we saw the rise in readership of the Journal, and for me it was interesting to see how the Journal connects to the tens of thousands of academicians and industry professionals of the pharmaceutical industry. Indeed the Journal plays and will continue to play a key role towards ensuring growth of the PDA. Wishing the new editorial team all the best.
Mia Ricci: It's been a wonderful 8 years supporting the editorial team of the Journal and serving the PDA community. Thank you to all our readers, authors, reviewers, and editors. Please continue your support and dedication to the Journal!
Govind Rao: It has been a privilege working with this team and pushing the boundaries of regulatory science. Regulatory science is different from traditional science in that it is requires an unusual perspective of trying to understand what could go wrong and the steps that need to be taken to prevent that. We have worked hard to create a system of rapid and fair peer review and hope that our community has benefited. Proudest moment: Finding out that our annual access is close to a million views! We wanted to make a difference, and it appears that people are reading the Journal in increasing numbers. Biggest surprise: Learning that glass can delaminate and end up in parenteral products—this is the kind of information that the focus on regulatory science provides.
We leave you with a sense of accomplishment and with our very best wishes for the incoming team and for a long and productive life for the Journal.
Thank you.
The PDA Journal Editorial Team
- © PDA, Inc. 2018